by Ben Paylor | Apr 3, 2013
Why should stem cell researchers use Twitter? Powerful news aggregator/information filter Able to engage/converse with other attendees at conferences & meetings Increase traffic, discussion and citations of your papers Create professional networks and...
by David Brindley | Mar 19, 2013
. Part 5 in Cell Therapy Industry 2027 series A short time ago, I had the immense pleasure of driving through the Napa Valley bathed in a warm pastel sunset. The view was accompanied by a two-chord soundtrack: the reassuring chinking of several bottles of the...
by Paul Krzyzanowski | Mar 13, 2013
[pullquote]In time, this purchase might make BioTime the company that Geron was supposed to be.[/pullquote]Avid watchers of the stem cell and regenerative medicine market have no doubt heard of Geron selling its stem cell assets to BioTime. Nature covered it in some...
by Ubaka Ogbogu | Feb 26, 2013
Patients contemplating medical travel for the purpose of receiving scientifically unproven stem cell treatments may wish to consider one more potential side effect: the possibility of losing their eligibility for health status-related compensation and benefits. In May...
by Nick Dragojlovic | Feb 20, 2013
– The regenerative medicine community greeted last month’s decision by the U.S. Supreme Court to uphold the legality of the Obama Administration’s stem cell policy with relief. The court found that federal funding of human embryonic stem cell (hESC) research is...
by Paul Krzyzanowski | Feb 14, 2013
– Nature kicked off 2013 with an unsettling article about how privileged information from research studies is being used to garner gigantic returns for investors, large and small. It’s not surprising, considering that one of the most egregious cases of so called...
Comments